SOURCE: Hamilton Thorne

Hamilton Thorne

August 19, 2015 16:38 ET

Hamilton Thorne Announces Continued Revenue and Net Income Growth for the Quarter Ended June 30, 2015

Net Income up 45%; Eighth Consecutive Quarter of Year Over Year Net Income Growth

BEVERLY, MA and TORONTO, ON--(Marketwired - Aug 19, 2015) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today reported operational and financial results for the quarter ended June 30, 2015.

The Company's strategy to focus on its core products in established markets continues to generate substantial improvements in financial performance and yield significant operating leverage. Revenues were up 1% for the quarter to $2.1 million. The Company continued to generate significant gains in net income (up 45%) and EBITDA (up 34%) attributable to strong expense controls and accretive earnings from our new product acquisition. Sales for the first six months of the year were up 3.7% to $4.3 million with net income improving 66% to $439,000 and EBITDA improving 43% to $593,000. Cash flow from operations for the first half increased 50% to $367,000.Trailing twelve month net income exceeded $1.0 million for the first time in the Company's history with earnings per share (basic and diluted) of $0.02.

"We are pleased to have performed well in the first half of 2015, as we continue to face headwinds in accelerating our sales growth due to the strength of the US dollar, which has led to significant pricing differentials versus the products of our mostly European-based competitors," said David Wolf, President and Chief Executive Officer of Hamilton Thorne Ltd. Mr. Wolf continued, "We have and will continue to offer incentives to our distributors to build market share in a manner that is consistent with our goals of enhancing both revenue growth and profitability. We are also continuing to focus more of our activities and resources on expanding the breadth of the products and services that we offer through our own development efforts and a strategy of selective acquisitions of complementary products and companies in our field."

    Three and Six Month Periods Ending June 30
    Three Months   Six Months
Statement of Operations   2015   2014   2015   2014
Sales   $2,234,699   $2,214,501   $4,332,596   $4,179,784
Gross profit   1,453,087   1,439,486   2,768,945   2,656,344
Operating expenses   1,090,840   1,169,528   2,217,506   2,282,064
Net income   303,288   209,392   438,800   264,146
EBITDA   388,559   289,889   592,697   414,142
Basic earnings per share   $0.005   $0.004   $0.007   $0.005
Diluted earnings per share   $0.004   $0.004   $0.006   $0.005

All amounts are in US dollars, unless specified otherwise, and results, with the exception of EBITDA, are expressed in accordance with the International Financial Reporting Standards ("IFRS").

Financial statements and accompanying Management Discussion and Analysis for the periods are available on and the Hamilton Thorne website.

About Hamilton Thorne Ltd. (

Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems for the fertility, stem cell and developmental biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in regenerative medicine, stem cell research and fertility markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical instruments, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses. 

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

The Company has included earnings before interest, income taxes, depreciation and amortization, ("EBITDA") as a non-IFRS measure, which is used by management as a measure of financial performance. See section entitled "Use of Non-IFRS Measures" in the Company's Management Discussion and Analysis for the periods covered for further information.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at

Contact Information

  • For more information, please contact:

    David Wolf
    President & CEO
    Hamilton Thorne Ltd.
    Email Contact

    Michael Bruns
    Hamilton Thorne Ltd.
    Email Contact